title: A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis.
abstract: BACKGROUND
  Both infliximab (IFX) and tacrolimus (Tac) are effective for inducing clinical remission in patients with ulcerative colitis (UC). However, no randomized study has addressed the relative efficacies of IFX and Tac for patients with moderate to severe UC. This study aimed to conduct a retrospective study on the relative efficacy of IFX and Tac in patients with moderate to severe UC, using an inverse probability of treatment weighting (IPTW) technique to adjust background factors statistically.
  
  
  METHODS
  Between July 2009 and March 2016, data obtained from 122 patients with moderate to severe UC who were treated with either IFX (n = 58) or Tac (n = 64) were analyzed retrospectively. We compared the short-term therapeutic efficacy between the IFX group and Tac group using IPTW technique.
  
  
  RESULTS
  The clinical remission rate at 14 weeks after treatment was 37.9% (22/58) in the IFX group and 50% (32/64) in the Tac group, respectively. The efficacy of IFX and Tac for clinical remission rate was not different according to univariate (Odds ratio [OR] 1.64, 95% confidence interval [CI] 0.80-3.37 P = 0.18) and multivariate analyses (OR 2.19, 95% CI 0.85-5.61, P = 0.10). After the background and confounders factors were adjusted by using IPTW based on propensity score, the efficacy of IFX and Tac for clinical remission rate was not differed statistically (OR, 1.483; 95% CI, 0.581-3.785; P = 0.409) Conclusion. IFX and Tac have equivalent short-term efficacies for induction in patients with moderate to severe UC.
authors.affiliation: 545-8585.
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Yamagami
authors.affiliation: 545-8585.
authors.forename: Yu
authors.initials: Y
authors.lastname: Nishida
authors.affiliation: 545-8585.
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Nagami
authors.affiliation: 545-8585.
authors.forename: Shuhei
authors.initials: S
authors.lastname: Hosomi
authors.affiliation: 545-8585.
authors.forename: Tomomi
authors.initials: T
authors.lastname: Yukawa
authors.affiliation: 545-8585.
authors.forename: Koji
authors.initials: K
authors.lastname: Otani
authors.affiliation: 545-8585.
authors.forename: Fumio
authors.initials: F
authors.lastname: Tanaka
authors.affiliation: 545-8585.
authors.forename: Koichi
authors.initials: K
authors.lastname: Taira
authors.affiliation: 545-8585.
authors.forename: Noriko
authors.initials: N
authors.lastname: Kamata
authors.affiliation: 545-8585.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Tanigawa
authors.affiliation: 545-8585.
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Shiba
authors.affiliation: 545-8585.
authors.forename: Toshio
authors.initials: T
authors.lastname: Watanabe
authors.affiliation: 545-8585.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Fujiwara
mesh_terms: D000328:Adult; D000368:Aged; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005765:Gastrointestinal Agents; D000069285:Infliximab; D016559:Tacrolimus
keywords: infliximab; inverse probability of treatment weighting; remission rate; tacrolimus; ulcerative colitis